TL;DR: A reader asked me whether the GHK-Cu copper peptide products she was using as antiaging actives were doing anything. The honest answer involves separating two literatures: the wound-healing data, which is substantial and supports real biological activity, and the cosmetic skin data, which is thinner and more dependent on formulation than brands acknowledge. Here is what the studies actually show.
A reader asked me last month whether the copper peptide serums she was layering into her routine were doing anything she could verify. She had been using a GHK-Cu product daily for eight months and was not sure if she was seeing peptide effects or wishful thinking effects. She wanted to know what the actual data said.
I want to be careful in this article because GHK-Cu is one of the more interesting molecules in the cosmetic peptide space, and also one where the marketing has run far ahead of the cosmetic-skin data. There are two distinct bodies of literature: the wound healing literature, which is substantial and supports meaningful biological activity, and the cosmetic skin literature, which is thinner and uses outcome measures that do not always translate to what consumers expect from the products. Here is how I read both.
What the molecule is and where it came from
GHK is a tripeptide of glycine-histidine-lysine. It was discovered by Loren Pickart in 1973 as a factor in human plasma that promoted hepatocyte function in cell culture. The peptide binds copper with high affinity, forming a 1:1 complex (GHK-Cu) that has biological activity distinct from either component alone. Pickart’s subsequent work over four decades has mapped the gene expression effects, the wound healing applications, and the protein interactions.
The Pickart 2008 review (PMID: 18644225) is the cleanest summary of the early work. The peptide has demonstrated effects on collagen synthesis, glycosaminoglycan production, fibroblast proliferation, and antioxidant enzyme expression in cell culture. Animal studies showed accelerated healing of ulcers, burns, and surgical wounds. The mechanism involves copper delivery to enzymes that require it as a cofactor (lysyl oxidase, superoxide dismutase) plus direct gene regulatory effects through pathways that include the SOD enzymes and matrix metalloproteinases.
The Pickart 2018 review (PMID: 29986520) extended this with broader genomic analysis. The Connectivity Map database showed that GHK exposure produced gene expression signatures matching known therapeutics for tissue repair and antiaging interventions. The peptide modulates the expression of around 4,000 genes in the human genome, with effects on inflammation, oxidative stress, and tissue remodeling pathways. This is unusually broad pharmacology for a single tripeptide and is part of why the molecule attracts continued research attention.
The Pickart 2015 review (PMID: 26236731) focused specifically on skin regeneration. The review summarized data on dermal collagen synthesis, photodamage repair, and barrier function. Most of the cited evidence comes from cell culture and small clinical studies funded by ProCyte (Pickart’s company) and its successors. The data is consistent but the publication ecosystem is concentrated around a small group of researchers.
The wound-healing pedigree
The most rigorous clinical work on GHK-Cu is in wound healing rather than cosmetic skin. Mulder 1994 (PMID: 17147644) tested topical GHK-Cu on diabetic ulcers in a randomized controlled trial. The peptide-treated group had faster wound closure and better healing quality than the placebo group. This is a clinically meaningful outcome with hard endpoints (wound area, time to closure).
Subsequent wound-healing work over the 1990s and 2000s expanded to burns, surgical wounds, pressure sores, and corneal ulcers. The peptide is incorporated into a small number of wound-care products. The dosing in wound-care contexts is high (1 to 5 percent peptide solutions applied to disrupted skin) and the access to the dermis is direct (the wound bed is open tissue, bypassing the stratum corneum barrier).
This is where the wound-healing-to-cosmetic translation problem begins. The cosmetic skin formulations typically contain GHK-Cu at 0.01 to 0.1 percent in vehicles designed for intact skin. The peptide must penetrate the stratum corneum, reach the viable epidermis or dermis, and act on fibroblasts or keratinocytes at concentrations that retain biological activity. The penetration data for GHK-Cu through intact stratum corneum is limited, and the available evidence suggests modest penetration that may or may not reach the concentrations needed for the effects demonstrated in wound healing.
The cosmetic skin data
The Leyden 2002 study, presented as a conference abstract, is the most-cited industry-funded clinical work on GHK-Cu for cosmetic skin. The trial tested a copper peptide facial cream in 67 women over 12 weeks. The reported outcomes included improvements in wrinkles, skin density on ultrasound, and clinical photographs assessed by graders. The effect sizes were modest and the methodology has been criticized for grader blinding and outcome selection.
I want to be honest about the cosmetic literature: there are no large randomized controlled trials of GHK-Cu in cosmetic formulations published in peer-reviewed journals with hard endpoints and pre-registered protocols. There are case reports, industry-sponsored studies, mechanistic cell culture work, and clinical observations from dermatologists who use the products. This is not the same evidence base as exists for retinoids, vitamin C, or alpha hydroxy acids.
The mechanism of action papers are stronger than the clinical efficacy papers. GHK-Cu does activate the pathways the literature describes. Whether it does so at concentrations achievable in cosmetic skin penetration and at effect sizes that produce visible cosmetic improvement is a separate question that the available data answers less clearly.
The contrarian section
I want to walk through three contrarian points about the GHK-Cu cosmetic category.
First, the copper question. Copper is essential for the biological activity of GHK-Cu, and the peptide is designed to deliver copper to enzymes. But topical copper at meaningful concentrations causes oxidative reactions in the presence of vitamin C, alpha hydroxy acids, and several other common skincare actives. The standard recommendation is to never layer copper peptides with vitamin C or strong acids. In practice, this means that if you use a vitamin C serum in the morning and a copper peptide serum at night, the residual vitamin C in the skin may interact with the copper peptide in ways that reduce both. The data on this is mostly bench chemistry rather than human skin studies, but the precautionary advice from chemists is to space them by at least 12 hours or alternate days.
Second, the peptide stability question. GHK-Cu is sensitive to formulation pH, oxidation, and certain preservatives. The peptide is most stable at slightly acidic to neutral pH, away from light, and in low-oxygen environments. Many cosmetic formulations do not maintain these conditions. The Niod Copper Amino Isolate Serum and a small number of high-end products are formulated specifically to maintain copper peptide stability with anhydrous bases or separated activation systems. Most £20-£40 copper peptide products in single-phase aqueous formulations have unverified peptide stability through their shelf life. The product on shelf may not contain the peptide concentration the label claims by the time you buy it.
Third, the comparison-to-alternatives question. The interventions with the largest published effect sizes on the outcomes copper peptides target (wrinkles, skin density, photodamage repair) are retinoids and sustained sunscreen use. The effect sizes for GHK-Cu in cosmetic application, where measurable, are smaller than for tretinoin or adapalene. A copper peptide serum added to a routine that does not already include a retinoid is probably less effective than adding a retinoid and skipping the copper peptide. The honest framing is that GHK-Cu is a complementary active that may add some incremental benefit on top of an established regimen, not a primary active that drives results.
What might still be true about GHK-Cu
I do not want to overclaim the skepticism. The wound-healing data is substantial enough that GHK-Cu is doing real things in real tissue under real conditions. The gene expression effects are documented across multiple independent labs. The mechanism is biologically coherent.
The most defensible cosmetic use cases I can think of: post-procedural skin recovery (after microneedling, ablative laser, or chemical peels) where the stratum corneum is partially disrupted and the peptide can reach the dermis at meaningful concentrations. This is essentially a small-wound-healing context, and the literature supports it more clearly than intact-skin cosmetic use. Many dermatologists use copper peptide products in this window for this reason.
The second defensible use: as an adjunct in mature skin where collagen synthesis is declining and any incremental boost is valuable. The effect size may be small, but on top of retinoids and SPF, it may be worth the addition for users who are already optimized on the foundational actives.
The least defensible use: as a standalone antiaging routine in someone who is not using a retinoid, not using SPF consistently, and is not addressing the more impactful variables first. The peptide cannot make up for the absence of the higher-evidence interventions.
What I would tell my past self
I spent about two years using a £60 GHK-Cu serum and assumed I was getting the antiaging benefit the marketing promised. The serum was the third or fourth most expensive item in my routine. When I read the actual cosmetic clinical data with appropriate skepticism, I realized I had been buying the wound-healing-implied benefit rather than the cosmetic-trial-demonstrated benefit. The two are not the same.
The shift was to demote GHK-Cu in my mental hierarchy of antiaging interventions. Retinoids first, sunscreen first, antioxidants second, peptides as adjuncts. When I removed the copper peptide from my routine for six months as a test, I could not see any change attributable to its absence. When I added it back, I could not see a change attributable to its presence. The honest read is that the effect was below my ability to detect in real-world conditions, even if the peptide was doing something real at the cellular level.
I do still recommend GHK-Cu in two scenarios: post-procedural recovery, and as an additional active in routines already optimized on the foundational layers. For the reader who asked me about her eight-month use: my best guess is that the visible improvements were mostly from the rest of her routine (she was also using tretinoin and SPF) with the copper peptide adding a marginal contribution. Whether that marginal contribution justifies the cost is a question only she can answer based on her budget and priorities.
FAQ
Are all copper peptides the same as GHK-Cu?
No. GHK-Cu specifically refers to the glycine-histidine-lysine tripeptide complexed with copper. Other copper peptides exist (AHK-Cu is one example) with different sequences and different biological activities. Most products labeled “copper peptide” use GHK-Cu, but some use blends with other tripeptides. The published research is overwhelmingly on GHK-Cu, so other copper peptides have less evidence behind them.
Can copper peptides cause hair growth on the face?
Copper peptides are studied for scalp hair growth (AHK-Cu derivatives, lipopeptides) with some positive findings. Whether topical use on facial skin produces vellus hair stimulation is theoretically possible but not commonly reported. The concentrations and formulations used in facial products are different from those used in hair growth products. The risk of unwanted facial hair from cosmetic copper peptide use appears to be low based on the absence of widespread reports.
Should I avoid copper peptides if I’m using a vitamin C serum?
If you are using both, separate them by at least 12 hours and ideally use them on alternate days. Vitamin C and copper peptides can produce oxidation reactions that reduce the effective concentration of both actives. The risk is theoretical based on chemistry rather than well-documented in clinical use, but the precautionary spacing is low-cost. Morning vitamin C and evening copper peptide on alternate days is a reasonable structure.
What is the difference between Niod CAIS and The Ordinary Buffet + Copper Peptides?
The Niod product (Copper Amino Isolate Serum 3) is formulated as an anhydrous serum to maintain peptide stability and uses a higher peptide concentration. The Ordinary product blends multiple peptides at lower concentrations in an aqueous base. The Niod approach is more formulation-conservative for peptide preservation but more expensive. The Ordinary approach is more accessible but the peptide stability through shelf life is less well-characterized. For a user committed to copper peptides, the Niod formulation is the more defensible choice on chemistry grounds.
How long should I trial a copper peptide before deciding it works?
The cosmetic effects, where present, develop slowly. The published clinical trials run for 8 to 12 weeks. If you are going to evaluate a copper peptide product, give it at least three months of consistent use without changing other variables in your routine. If you cannot perceive a difference after three months on top of an otherwise stable routine, the effect is likely below your detection threshold and the product is not worth continuing. Be honest with yourself about what you are seeing versus what you want to see.
Related Elelaf tools
Sources
- Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. 2008;19(8):969-988. PMID: 18644225
- Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. PMID: 29986520
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015;2015:648108. PMID: 26236731
- Mulder GD, Patt LM, Sanders L, et al. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper. Wound Repair Regen. 1994;2(4):259-269. PMID: 17147644
- Leyden J, Stephens T, Finkey M, Appa Y, Barkovic S. Skin care benefits of copper peptide containing facial cream. American Academy of Dermatology 60th Annual Meeting; 2002. Presentation abstract
References
- Schagen SK. Topical peptide treatments with effective anti-aging results. Cosmetics. 2017. PubMed.
- Lupo MP, Cole AL. Cosmeceutical peptides. Dermatol Ther. 2007. PubMed.
Have a question about “Copper peptide GHK-Cu: the wound-healing pedigree and the cosmetic-skin question”?
Ask our editorial desk. Best questions become full follow-up articles, reviewed by our medical reviewer. No medical advice given in private — answers run as articles or not at all.